All In Biotech

Drug Trial Radar · NCT06154447

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Dec 12, 2023

Primary completion

Jul 10, 2026

Study completion Jul 10, 2026

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Conditions

  • Cystic Fibrosis

Interventions

  • VX-828Drug

    Suspension for Oral Administration

  • PlaceboDrug

    Suspension for Oral Administration

  • ItraconazoleDrug

    Solution for Oral Administration

  • MidazolamDrug

    Syrup for Oral Administration

  • TezacaftorDrug

    Tablets for Oral Administration

  • VX-118Drug

    Tablets for Oral Administration

  • PlaceboDrug

    Suspension and Tablets for Oral Administration

  • DeutivacaftorDrug

    Tablets for Oral Administration

  • VX-828Drug

    Tablets for Oral Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 67)
  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
  3. Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 80)
  4. Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Signing of Informed Consent Form (ICF) up to End of Study (Up to Day 111)
  5. Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of ItraconazoleTime frame: From Day 1 up to Day 71
  6. Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of ItraconazoleTime frame: From Day 1 up to Day 71
  7. Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVATime frame: From Day 1 up to Day 30
  8. Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVATime frame: From Day 1 up to Day 30

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Joe DiMaggio Cycstic Fibrosis & Pulmonary Center

    Hollywood, Florida

  • AdventHealth Medical Group Pulmonology at Orlando Ridgewood

    Orlando, Florida

  • Altasciences Clinical Kansas

    Overland Park, Kansas

  • Kentucky Children's Hospital

    Lexington, Kentucky

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Minnesota -Pulmonology

    Minneapolis, Minnesota

  • Billings Clinic, Pediatric Pulmonary Dept.

    Billings, Montana

  • New York Medical College

    Hawthorne, New York

  • ProMedica Toledo Children's Hospital & ProMedica Central Physicians, LLC

    Toledo, Ohio

  • Cook Children's Pulmonology

    Fort Worth, Texas

  • University of Utah Hospital - Pulmonology

    Salt Lake City, Utah

  • Vermont Lung Center

    Colchester, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.